Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27549713 | 0.93 | CA1 (0.59) | CA1FDPSACE2GPR84 | |
| SCHEMBL8114261 | 0.91 | CA1 (0.57) | CA1FDPSCA2ACE2GPR84 | |
| SCHEMBL8249566 | 0.85 | CHRM1 (0.40) | CA1FDPSMAPK1ACE2 | |
| SCHEMBL15386601 | 0.82 | CA1 (0.52) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL7939279 | 0.82 | CA1 (0.47) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL6674983 | 0.81 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL3003475 | 0.81 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL6681186 | 0.81 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL15386600 | 0.80 | CA1 (0.45) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL7546267 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248928-B1 | REACTING STRONTIUM WITH A STERICALLY HINDERED ALCOHOL TO PRODUCE STRONTIUM ALKOXIDE; REACTING THE STRONTIUM ALKOXIDE WITH A BETA-DIKETONE TO FORM A STRONTIUM BETA-DIKETONATE ALCOHOL ADDUCT AND REMOVING THE ALCOHOL | INORGTECH LIMITED (GB) | 2001-06-19 | — | — | US | claimed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-6248928-B1 | REACTING STRONTIUM WITH A STERICALLY HINDERED ALCOHOL TO PRODUCE STRONTIUM ALKOXIDE; REACTING THE STRONTIUM ALKOXIDE WITH A BETA-DIKETONE TO FORM A STRONTIUM BETA-DIKETONATE ALCOHOL ADDUCT AND REMOVING THE ALCOHOL | INORGTECH LIMITED (GB) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CA1 3625/4885FDPS 1351/4885CA2 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.